Introduction

Oncology Reports

1021-335X 1791-2431

D.A. Spandidos

10.3892/or.2023.8656

OR-50-6-08656

Articles

P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions

Zhang

Jiayu

1 Li

Chenguang

1 Sun

Luanbiao

1 Sun

Denghua

2 * Zhao

Tiancheng

3 *

1Gastrointestinal Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China 2Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China 3Department of Endoscopy Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China

Correspondence to: Professor Denghua Sun, Department of Breast Surgery, China-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun, Jilin 130033, P.R. China, E-mail: sundenghua@jlu.edu.cn Dr Tiancheng Zhao, Department of Endoscopy Center, China-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun, Jilin 130033, P.R. China, E-mail: zhaotiancheng@jlu.edu.cn *

Contributed equally

12 2023

31 10 2023

50 6

219

05082022 03102022

2023

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Oxaliplatin (OXA)-containing regimens are used as first-line chemotherapy in colorectal cancer (CRC). However, OXA resistance remains a major challenge in CRC treatment. CRC cells that adapt to hypoxia can potentially develop OXA resistance, and the underlying molecular mechanisms still need to be further investigated. In the current study, the OXA drug sensitivity of two CRC cell lines, HCT116 (TP53^WT) and HT29 (TP53^MT), was compared under both normoxic and hypoxic conditions. It was found that under normoxic condition, HCT116 cells showed significantly higher OXA sensitivity than HT29 cells. However, both cell lines showed remarkable OXA resistance under hypoxic conditions. It was also revealed that P53 levels were increased after OXA and hypoxia treatment in HCT116 cells but not in HT29 cells. Notably, knocking down P53^WT decreased normoxic but increased hypoxic OXA sensitivity in HCT116 cells, which did not exist in HT29 cells. Molecular analysis indicated that P53^WT activated microRNA (miR)-26a and miR-34a in OXA treatment and activated miR-23a in hypoxia treatment. Cell proliferation experiments indicated that a high level of miR-23a decreased OXA sensitivity and that a high level of miR-26a or miR-34a increased OXA sensitivity in HCT116 cells. Additionally, it was demonstrated that miR-26a, miR-34a and miR-23a affect cell apoptosis through regulation of MCL-1, EZH2, BCL-2, SMAD 4 and STAT3. Taken together, the present findings revealed the dual function of P53 in regulating cellular chemo-sensitivity and highlighted the role of P53-miR interactions in the response of CRC cells to OXA chemotherapy under normoxic and hypoxic conditions.

colorectal cancer microRNA P53 oxaliplatin hypoxia

National Natural Science Foundation of China

81903380

Wanzhong Biological Technology Ltd. Co

3R2210279430

The present study was supported by grants from the National Natural Science Foundation of China (grant no. 81903380) and the Wanzhong Biological Technology Ltd. Co (grant no. 3R2210279430).

Introduction

Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. In China, the incidence and mortality of CRC are increasing every year (1). Surgical resection is the mainstay of potentially curative treatments for CRC; however, prognosis is generally poor due to locoregional recurrence with resection alone (2).

Cytotoxic chemotherapy is another mainstay of treatment for CRC patients. Oxaliplatin (OXA) is a third-generation chemotherapy drug of the diamino-cyclohexane platinum family (3,4). Due to potent in vitro cytotoxicity and in vivo antitumor activity, OXA-containing regimens are effectively used as first-line chemotherapy in CRC. However, de novo and acquired OXA resistance remains a major challenge in CRC treatment (5). The acquisition of OXA resistance in CRC is multi-factorial and includes the following: cellular transport and detoxification systems (copper transporters, solute carrier transporters and ATP-binding cassette transporters), OXA-induced DNA adduct repair and alterations in key cell death-related genes and/or tumor suppressors (p53, Bcl-2 family and MMP7) (6–9).

Hypoxia is a common feature of the tumor microenvironment that activates the expression of numerous genes associated with cell growth, angiogenesis, metastasis and drug resistance (10–13). Cells adapting to hypoxia have been demonstrated to reduce the cytotoxicity of numerous drugs, such as OXA and 5-fluorouracil (5-FU) (14,15). Therefore, elucidating the underlying mechanisms of hypoxia-induced drug resistance and developing more effective therapeutic regimens to overcome hypoxia-induced drug resistance are clinical priorities.

Accumulating evidence has shown that microRNAs (miRs) play an important role in acquired drug resistance in colorectal carcinoma (CRC). miRs can act as hypoxia sensors and their levels are altered consistently in CRC cells (16). Nijhuis et al (16) indicated that treatment with miR-21 and miR-30d antagonists sensitized hypoxic CRC cells to 5-FU. Xu et al (17) indicated that hypoxia-inducible transcription factor 1α (HIF-1α)-mediated suppression of miR-338-5p conferred OXA resistance in CRC cells.

P53 is a stress-inducible transcription factor that regulates numerous downstream genes, such as p21, Bax and GADD45, to exert regulatory functions in multiple signaling processes (18,19). TP53 mutation occurs in ~40-50% of CRC (20). The TP53 mutation status is closely related to the progression, drug resistance and outcome of CRC (21,22). However, the effect of TP53 mutation on drug resistance in CRC cells, particularly hypoxic CRC cells, and the role of miRs during this process remain to be elucidated.

The aim of the present study was to investigate how p53 affects hypoxia-induced OXA resistance by regulating miR expression in CRC.

Materials and methods <sec> <title>Cell lines and cell culture

Human CRC cell lines HCT116 (TP53^WT) and HT29 (TP53^MT, c.818G>A (23), STR profiled) were purchased from Stem Cell Bank, Chinese Academy of Sciences. Cells were cultured in DMEM (HyClone; Cytiva) supplemented with 10% fetal bovine serum (Shanghai ExCell Biology, Inc.) and penicillin (100 U/ml)-streptomycin (100 µg/ml) (Sangon Biotech Co., Ltd.) and were maintained in a humidified 37°C incubator with 5% CO₂. Cells were passaged when they reached ~80% confluency and were regularly tested with Mycoplasma Test Kit (Shanghai Yeasen Biotechnology Co., Ltd.) to ensure the absence of mycoplasma contamination.

For OXA chemotherapy, OXA (MilliporeSigma) solution was prepared with cell culture medium and the working concentration is 5, 10, 20, 40 and 60 µM. Cells were cultured in OXA for 24 h before other experiments were carried out. For the hypoxic culture, cells were cultured at 37°C in a humidified O₂ (1%)/CO₂ (5%)/N2 (94%) incubator (Thermo Fisher Scientific, Inc.) for 24 h (17). Echinomycin (1 nM; MedChemExpress) dissolved in dimethyl sulfoxide (DMSO; MilliporeSigma) was added to cell culture medium for 24 h to inactivate HIF-1α (24).

Plasmid construction and cell transfection

For over-expressing P53^WT, the full-length CDS of human TP53^WT gene was synthesized and cloned into pcDNA3.1-neo vector. For knocking down P53, short hairpin (sh)RNA was synthesized and cloned into RNA interference vector pSilencer3.1-neo. The sequences of TP53 siRNA and scrambled siRNA were CACCATCCACTACAACTACAT (25) and GGATTTCGAGTCGTCTTAA. Stable cell lines were selected by G418 (800 µg/ml; Thermo Fisher Scientific, Inc.).

For plasmid transfection, HCT116 and HT29 cells were seeded in six-well plates 24 h prior to transfection in complete medium until they reached 40~60% confluency. Plasmid DNA was complexed with Lipofectamine 3000 and P3000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. Transfection media was removed and replaced with new media at 7 h post-transfection. miR-23a, −26a, −34a, −133a, −107a, −205 listed in Table I and NC-mimics were synthesized (Guangzhou RiboBio Co., Ltd.) and transfected into cells at a concentration of 10 nmol/ml with lipofectamine 3000. All the subsequent experimentations were carried out at 48 h post-transfection.

Cellular growth inhibition assay

Normal or transfected cells (at a density of 5,000 per well) in 100 µl complete medium were seeded in one well of 96-well plates. After culturing for 24 h, cells were treated with OXA and/or hypoxia for another 24 h, and 20 µl of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reagent (MTT; Beyotime Biotechnology) was added to each well and incubated at 37°C for 4 h. After removing the medium, the blue formazan was dissolved with 200 µl DMSO, and absorbance at 550 nm was measured. The cellular growth inhibition rate was defined as (1-OD₅₅₀ of the experimental group)/OD₅₅₀ of the control group ×100%.

Expression analysis of miRs and reverse transcription-quantitative polymerase chain reactions (RT-qPCR)

Total RNA of the OXA or hypoxia treated HCT116 cells was isolated with RNAzol (Sigma-Aldrich; Merck KGaA). A total of 31 miRs were selected and examined to analyze the effect of miRs on cellular chemoresistance (15 miRs) or cellular response to hypoxia (16 miRs).

RT-qPCR was conducted to detect the enrichment of relevant miRs. RNA was reverse transcribed to cDNA using Mir-X miRNA First-Strand Synthesis kit according to the manufacturer's instructionσ (Takara Biotechnology Co., Ltd.). Mir-X TB Green RT-qPCR kit (Takara Biotechnology Co., Ltd.) was used to conduct RT-qPCR reaction according to the manufacturer's instruction. U6 snRNA expression was used as endogenous control. The 5′ primer of U6 is CGCTTCGGCAGCACATATAC. PCR was performed on an ABI 7500 qPCR instrument (Applied Biosystems; Thermo Fisher Scientific, Inc.). The thermocycling conditions consisted of 10 sec at 95°C followed by 40 cycles at 95°C for 5 sec and 60°C for 35 sec. The abundance of miR was calculated using the formula of 2^−ΔΔCq (26). The primer sequences for amplification of miRs are listed in Table I.

Western blot analysis

Cells were lysed with lysis buffer (Beijing Solarbio Science & Technology Co., Ltd.) complemented with protease inhibitor cocktail (Sigma-Aldrich; Merck KGaA). Cell lysates were centrifuged at 12,000 × g at 4°C for 20 min to remove cell debris and insoluble material. Protein concentration was quantitated using the Bradford protein assay kit (Beyotime Institute of Biotechnology). Equal amounts of lysate (25 µg) were loaded per lane and proteins resolved by 5–10% SDS-PAGE gel, semi-dry transferred to 0.45-µm polyvinylidene fluoride membranes (EMD Millipore). The membranes were incubated in 5% skim milk in Tris-buffered saline Tween-20 (TBST; 10 mM Tris-Base, 150 mM NaCl, 0.05% Tween-20; pH 7.4) for 1 h at room temperature, followed by incubation with primary antibody in 5% skim milk in TBST at 4°C overnight. The membranes were then washed for 3×5 min in TBST, and then incubated in TBST-diluted secondary antibodies for 45 min at room temperature, followed by another 3×5 min washes with TBST. Protein-antibody binding was detected with ECL Western Blotting Substrate (Beijing Solarbio Science & Technology Co., Ltd.) followed by exposure of the membranes to X-ray film (Kodak). Protein expression levels were determined semiquantitatively by densitometric analysis with the Quantity One software (version 4.6.2; Bio-Rad Laboratories, Inc.). The following antibodies were used: anti-p53 (1:1,000; cat. no. sc-47698; Santa Cruz Biotechnology, Inc.), anti-BCL-2 (1:1,000; cat. no. 15071), anti-MCL-1 (1:1,000; cat. no. 39224), anti-EZH2 (1:1,000; cat. no. 5246), anti-STAT3 (1:1,000; cat. no. 9139), anti-SMAD4 (1:1,000; cat. no. 46535; all from Cell Signaling Technology, Inc.), anti-β-ACTIN (1:2,000; cat. no. sc-8432) and HRP-conjugated secondary antibody (1:3,000; cat. no. sc-2357; both from Santa Cruz Biotechnology, Inc.).

Statistical analysis

Statistical analysis was performed using SPSS software (version 19.0; IBM Corp.). Each experiment was repeated at least three times. Statistical significance was assessed by comparing the mean ± SD using an unpaired Student's t-test or ANOVA test followed by Fisher's Least Significant Difference, Bonferroni or Sidak post-hoc tests. *P<0.05 was considered to indicate a statistically significant difference.

Results <sec> <title>Hypoxia reduces OXA sensitivity in CRC cells

The response of HCT116 and HT29 cells to OXA was investigated under both normoxia and hypoxia. Both cell lines were treated with 5, 10, 20, 40 and 60 µM OXA and it was found that the cellular growth inhibition rates increased with the increase of drug concentration (Fig. 1A). Taking the 20 µM OXA treatment group as an example, the cellular growth inhibition rate of HCT116 cells was 56.6% under normoxic condition and 27.7% under hypoxic condition (Fig. 1B; P<0.01), while the cellular growth inhibition rate of HT29 cells was 35.7% under normoxic condition and 25.5% under hypoxic condition (Fig. 1B; P<0.05). The cellular growth change rate of HCT116 cells was 2.06 and of HT29 cells was 1.41 (Fig. 1C; P<0.05). These data suggested that HCT116 cells were more sensitive to OXA than HT29 cells under normoxic condition. Additionally, although hypoxia decreases the OXA sensitivity, it generated greater impact on HCT116 cells than HT29 cells.

TP53 status affects CRC cell drug sensitivity

TP53 status is the typical difference between HCT116 cells and HT29 cells. P53 expression was detected after both cell lines were treated with OXA and hypoxia and it was found that the P53 expression level of HCT116 cells increased significantly and of HT29 cells did not change considerably (Fig. 2A and B). P53 was then knocked down and cell drug sensitivity to 20 µM OXA was measured (Fig. 3A). Under normoxic condition, the cellular growth inhibition rate of HCT116 cells was 57.3% in the EV group and 40.8% in the shP53 group (Fig. 3B, left panel; P<0.01), while under hypoxic condition, the cellular growth inhibition rate of HCT116 cells was 28.6% in the EV group and 38.4% in the shP53 group (Fig. 3B, left panel; P<0.05). These data suggested that P53^WT plays different roles in HCT116 cell drug sensitivity, enhancing drug sensitivity under normoxic conditions but reducing drug sensitivity under hypoxic conditions. However, knocking down TP53 did not change HT29 cell response to OXA under either normoxia or hypoxia (Fig. 3B, right panel). The growth inhibition change rate also reflected this phenomenon (Fig. 3C).

P53 affects expression of miRs after OXA and hypoxia treatment

P53-miR interaction plays pivotal role in regulating CRC cell drug sensitivity (31). To directly reveal how P53 and miRs affect chemoresistance under hypoxia, 31 miRs that have been demonstrated to be correlated with chemoresistance or hypoxia in CRC were selected. By using RT-qPCR, the expression of miRs after HCT116 cells were treated with OXA or hypoxia was analyzed, and it was found that the expression level of miR-143, 26a, 34a, 133a, 149 and 195 were significantly increased after HCT116 cells were treated with OXA (Fig. 4A), while miR-23a, 27a, 107, 19a, 145, 205, 210 and 590 were significantly increased after HCT116 cells were treated with hypoxia (Fig. 4B). However, after TP53 was knocked down, the expression levels of miR-26a, 34a, 133a, 23a, 107 and 205 were decreased accordingly (Fig. 4C and D), indicating that these miRs were P53-induced miRs or interact with P53.

miRs affect HCT116 cell OXA sensitivity depending on P53<sup>WT</sup>

The effects of these P53-related miRs were analyzed by overexpressing them in HCT116 cells. Cellular growth inhibition assay showed that miR-23a decreased OXA sensitivity, whereas miR-26a and miR-34a increased OXA sensitivity. However, miR-133a, 107 and 205 did not affect cell drug sensitivity (Fig. 5).

Then the association between miRs and P53 status was analyzed. The expression levels of miRs in HT29 cells (TP53^MT) were first detected and it was identified that OXA- or hypoxia-treatment did not upregulate miR-26a, 34a and 23a (Fig. 6A). However, transfection of miR-23a decreased cellular growth inhibition rate and transfection of miR-26a and 34a increased cellular growth inhibition rate, which was similar as they were functioning in HCT116 cells (Fig. 6B). Notably, after introducing exogenous P53^WT to HT29 cells (Fig. 6C), it was revealed that miR-26a, 34a and 23a can be induced by OXA or hypoxia treatment (Fig. 6D). These data suggested that the effect of these 3 miRs on CRC cell drug sensitivity depends on P53^WT.

Hypoxia suppresses the expression of miR-26a and miR-34a

It can be observed from the aforementioned experiments that miR-23a, 26a and 34a are all driven by P53. However, it was strange that with hypoxia upregulating the level of P53, it only induced the expression of miR-23a instead of affecting the level of miR-26a and miR-34a. To address this issue, the level of miR-26a and miR-34a was examined after CRC cells were treated with hypoxia for 2, 8, 16, 24 and 48 h. It was demonstrated that hypoxia significantly suppressed the expression levels of these two miRs in both HCT116 and HT29 cells (Fig. 7A and B). However, administration of HIF-1α inhibitor echinomycin reversed the inhibition effect of hypoxia on miRs in HCT116 cells but not in HT29 cells (Fig. 7A and B). These data suggested that hypoxia and P53^WT synergistically altered expression of miRs.

miRs regulate cellular apoptosis-related factors and modulate drug sensitivity

The possible molecular mechanism of how miR-23a, 26a and 34a modulate OXA sensitivity was further investigated. According to previous studies, miR-26a and 34a may activate BCL-2, MCL-1, EZH2, SMAD 4 and STAT3 (54–58). In the present study, it was also demonstrated that miR-26a could decrease the expression levels of MCL-1, EZH2 and BCL-2 (Fig. 8A) and miR-34a could decrease the expression levels of SMAD4, STAT3 and BCL-2 (Fig. 8B). However, high level of miR-23a could reverse the OXA-induced suppression of MCL-1 and BCL-2 (Fig. 8C). These data possibly explain why P53^WT-induced miRs promote OXA sensitivity under normoxic conditions but hypoxia enhances OXA resistance in CRC cells.

Discussion

Since OXA is a major antitumor drug for CRC chemotherapy, finding useful biomarkers and potential molecular mechanisms of OXA resistance is significant for adjusting the treatment regimen for patients with CRC. The hypoxic tumor microenvironment has a pivotal influence on behavior of tumor cells. Impaired drug penetration into hypoxic regions of tumors and adaptive cellular response to hypoxia are considered to account for the reduction of cytotoxicity of numerous drugs in multiple cancer types (59–61).

In the present study, the OXA sensitivity of HCT116 and HT29 cells was firstly examined. The cell proliferation inhibition results clearly showed that hypoxia affects the OXA sensitivity of both cell lines. Notably, hypoxia caused a greater impact on HCT116 cells than on HT29 cells. Since the major difference between these two cell lines is the TP53 genotype (HCT116 is TP53^WT and HT29 is TP53^MT), it was hypothesized that P53 may play a key role in hypoxia-induced OXA resistance. To test this hypothesis, the P53 expression level was determined after HCT116 and HT29 cells were treated with 20 µM OXA or hypoxia and it was found that the P53^WT level in HCT116 cells was significantly increased, while the P53^MT level in HT29 cells did not change considerably. P53 was then knocked down and drug sensitivity was examined. Surprisingly, it was found that P53 had dual effects on regulating the OXA sensitivity of HCT116 cells: It promoted OXA sensitivity under normoxic conditions and reduced OXA sensitivity under hypoxic conditions.

miRs are critical transcriptional mediators and epigenetic regulators in multiple biological activities, including tumorigenesis, angiogenesis, cell senescence, metabolism and drug resistance (62–66). There is a great number of miRs in cells and thousands of human genes are miR targets. Compared with transcriptional regulation, miR regulation is fast and flexible, and miRs may regulate cellular behaviors without affecting basic biological activities. Previous studies have indicated that there are numerous P53-dependent miRs (67,68). Most of these miRs have P53 response elements in their promoter region, such as miR-145, −34s, −202, −1204, −1206, −10b and −23b (69–72). This suggests that although P53 is upregulated by OXA and hypoxia, it may activate different miR groups under these two stimuli, which can explain the distinct effects of P53 on OXA sensitivity under normoxic and hypoxic conditions. By referring to previous research findings, 31 OXA- or hypoxia-induced miRs were selected. Since numerous of these miRs are P53 dependent (Table I) (73–76), they are probably involved in the regulation of resistance by P53. RT-qPCR results indicated that among these miRs, 6 miRs were induced by OXA, and 8miRs were induced by hypoxia. The following P53 deprivation experiments indicated that miR-26a-5p, miR-34a-5p and miR-133a-3p levels were associated with P53 in OXA treatment conditions, while miR-23a-3p, miR-107 and miR-205-5p were altered in hypoxia treatment conditions. Further miR overexpression experiments indicated that among the aforementioned six miRs, only miR-23a-3p (decreases OXA resistance), miR-26a-5p (increases OXA sensitivity) and miR-34a-5p (increases OXA sensitivity) were involved in the OXA response. These three miRs were then introduced into TP53^MT HT29 cells, and a similar phenomenon was observed. P53^WT restoration experiments in HT29 cells clearly indicated that miR-26a-5p, miR-34a-5p and miR-23a-3p are P53 dependent. Taking these data together, it could be concluded that in P53^WT HCT116 cells, P53^WT protein plays two roles in regulating cell sensitivity to OXA: Under normoxic conditions, OXA stimulates P53^WT expression and therefore induces miR-26a-5p and miR-34a-5p, which renders cells sensitive to OXA; by contrast, under hypoxic condition, although P53^WT is also upregulated, it induces miR-23a and decreases cell sensitivity to OXA.

Hypoxia activates HIF signaling pathways in cancer cells, which can transactivate a wide variety of transcripts including miR transcripts (77). To further confirm that miR-26a-5p and miR-34a-3p are specifically induced by hypoxia, echinomycin was used to inactivate HIF-1α, and it was found that miR-26a-5p and miR-34a-3p could not be sustained without HIF-1α in both HCT116 and HT29 cells. These data indicated that although P53^WT can be used to regulate these two miRs under hypoxic conditions, HIF-1α is necessary for their stable expression.

miRs regulate drug sensitivity through modulation of numerous cellular apoptosis- and gene transcription-related factors. For example, Zhou et al (78) reported that miR-26a inhibits bladder cancer cell proliferation through inhibition of EZH2; Li et al (79) showed that knocking down EZH2 promotes OXA-induced cell cytotoxicity in OXA-resistant HT29 cells; Gao et al (55) reported that miR-26a inhibits breast cancer cell proliferation through repression of MCL-1; Yang et al (56) reported that miR-26a decreases Bcl-2 expression and that suppression of miR-26a causes cisplatin resistance in human non-small cell lung cancer. These findings supported our statement that P53^WT-induced miR-26a overexpression promotes OXA sensitivity in HCT116 cells. Similarly, miR-34a may promote OXA sensitivity through interactions with SMAD4, STAT3 and BCL-2 (58,80–82). The underlying molecular mechanisms for the association between P53^WT-induced miR-23a overexpression and hypoxia-mediated acquired OXA resistance were also investigated. Western blot results clearly showed that OXA suppressed the expression of the tumor antiapoptotic molecules MCL-1 and BCL-2. However, administration of miR-23a mimics restored their levels. Numerous studies have reported the oncogenic and promoting drug resistance property of miR-23a in cancers (83–86). Jin et al (39) reported that hypoxia led to an upregulation of miR-23a in CRC cells. Xu et al (87) found that sinomenine exerts an antitumor effect by downregulating miR-23a, and transfection of miR-23a-3p increased the level of BCL-2 in PC3 cells. Zhang et al (88) also revealed that miR-23a-3p inhibited the expression of BAX, promoted the expression of BCL-2 and inhibited the apoptosis of U937 cells. These investigations were in line with the present findings.

In summary, in the present study, the role of P53 in OXA-induced cellular apoptosis in CRC was investigated and it was identified that under normoxic conditions, P53 may promote cell apoptosis through activation of miR-26a and miR-34a, whereas under hypoxic conditions, P53 may induce OXA resistance through the activation of miR-23a. The present findings revealed the dual function of P53 in regulating cell apoptosis and highlighted the role of P53-miR interactions in the response of CRC cells to OXA under normoxic and hypoxic conditions (Fig. 9). These findings may provide deep insight into the molecular mechanism of antitumor drug resistance and a novel idea to overcome drug resistance in clinical cancer treatment. However, to deeply understand the crosstalk between P53 and the miR group, the identification of more research targets, particularly through data mining and bioinformatics analysis, is still needed.

Acknowledgements

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

TZ and DS contributed to the conception and design of the study. JZ and CL contributed to the acquisition, analysis and interpretation of data. LS analyzed the data and was involved in performing the experiments. DS drafted the work. TZ revised it critically for important intellectual content. All authors confirm the authenticity of all the raw data and read and approved the final version of the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References 1

Cai

Wang

Looking back 2018-focused on colorectal cancer

Zhonghua Wei Chang Wai Ke Za Zhi229162019(In Chinese)

30703787

Quirke

Durdey

Dixon

Williams

Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision

Lancet29969991986

10.1016/S0140-6736(86)92612-7

2430152

Hsu

Chen

Baskaran

Lin

Day

Lin

Vijaya Padma

Kuo

Huang

Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis

J Cell Physiol233545854672018

10.1002/jcp.26406

29247488

Yang

Zhou

Tong

Sun

Qing

Sun

Yang

Jiang

Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell lines

Sci Rep6330782016

10.1038/srep33078

27609465

Meads

Gatenby

Dalton

Environment-mediated drug resistance: A major contributor to minimal residual disease

Nat Rev Cancer96656742009

10.1038/nrc2714

19693095

Martinez-Balibrea

Martínez-Cardús

Ginés

Ruiz de Porras

Moutinho

Layos

Manzano

Bugés

Bystrup

Esteller

Abad

Tumor-related molecular mechanisms of oxaliplatin resistance

Mol Cancer Ther14176717762015

10.1158/1535-7163.MCT-14-0636

26184483

Plasencia

Martinez-Balibrea

Martinez-Cardús

Quinn

Abad

Neamati

Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells

Int J Oncol292252352006

16773204

Pedraz-Cuesta

Christensen

Jensen

Bunch

Romer

Brünner

Stenvang

Pedersen

The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells

BMC Cancer154112015

10.1186/s12885-015-1405-8

25981639

Liao

Song

Chang

Jia

Xiao

Ren

Zhang

Jia

Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma

BMC Cancer20312020

10.1186/s12885-019-6480-9

31931755

Hubbi

Semenza

Regulation of cell proliferation by hypoxia-inducible factors

Am J Physiol Cell Physiol309C775C7822015

10.1152/ajpcell.00279.2015

26491052

Pugh

Ratcliffe

Regulation of angiogenesis by hypoxia: Role of the HIF system

Nat Med96776842003

10.1038/nm0603-677

12778166

Gilkes

Semenza

Wirtz

Hypoxia and the extracellular matrix: Drivers of tumour metastasis

Nat Rev Cancer144304392014

10.1038/nrc3726

24827502

Tang

Chen

Bao

Mahara

Yatim

SMJM

Oguz

Lee

Feng

Cai

Tan

Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer

Proc Natl Acad Sci USA115E5990E59992018

10.1073/pnas.1801348115

29891662

Roberts

Williams

Cowen

Barathova

Eustace

Brittain-Dissont

Tilby

Pearson

Ottley

Stratford

Dive

Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells

Br J Cancer101129012972009

10.1038/sj.bjc.6605311

19755992

Gariboldi

Taiana

Bonzi

Craparotta

Giovannardi

Mancini

Monti

The BH3-mimetic obatoclax reduces HIF-1α levels and HIF-1 transcriptional activity and sensitizes hypoxic colon adenocarcinoma cells to 5-fluorouracil

Cancer Lett3641561642015

10.1016/j.canlet.2015.05.008

25979228

Nijhuis

Thompson

Adam

Parker

Gammon

Lewis

Bundy

Soga

Jalaly

Propper

Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance

Hum Mol Genet26155215642017

10.1093/hmg/ddx059

28207045

Zhan

Yuan

Qiu

Wang

Fan

Wang

Cao

Shen

Hypoxia induces drug resistance in colorectal cancer through the HIF-1α/miR-338-5p/IL-6 feedback loop

Mol Ther27181018242019

10.1016/j.ymthe.2019.05.017

31208913

Therachiyil

Haroon

Sahir

Siveen

Uddin

Kulinski

Buddenkotte

Steinhoff

Krishnankutty

Dysregulated phosphorylation of p53, autophagy and stemness attributes the mutant p53 harboring colon cancer cells impaired sensitivity to oxaliplatin

Front Oncol1017442020

10.3389/fonc.2020.01744

32984059

Shang

Wei

Inhibition of SMYD2 sensitized cisplatin to resistant cells in NSCLC through activating p53 pathway

Front Oncol93062019

10.3389/fonc.2019.00306

31106145

Takayama

Miyanishi

Hayashi

Sato

Niitsu

Colorectal cancer: Genetics of development and metastasis

J Gastroenterol411851922006

10.1007/s00535-006-1801-6

16699851

Huang

Sun

Zhou

Chen

Xia

Lai

Zhang

Mutations of key driver genes in colorectal cancer progression and metastasis

Cancer Metastasis Rev371731872018

10.1007/s10555-017-9726-5

29322354

Sui

Kong

Wang

Fang

Chen

Wang

Jin

JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy

Sci Rep446942014

10.1038/srep04694

24733045

Ikediobi

Davies

Bignell

Edkins

Stevens

O'Meara

Santarius

Avis

Barthorpe

Brackenbury

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set

Mol Cancer Ther5260626122006

10.1158/1535-7163.MCT-06-0433

17088437

Park

Shim

Lee

Kim

Echinomycin and a novel analogue induce apoptosis of HT-29 cells via the activation of MAP kinases pathway

Pharmacol Res502012072004

10.1016/j.phrs.2004.01.005

15177310

Kim

Lee

Bonifant

Ressom

Waldman

Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA

Mol Cell Biol276626772007

10.1128/MCB.00537-06

17060456

Livak

Schmittgen

Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method

Methods254024082001

10.1006/meth.2001.1262

11846609

Meng

Sun

Zhou

Han

Zhou

Jiang

Wang

LINC00460-miR-149-5p/miR-150-5p-mutant p53 feedback loop promotes oxaliplatin resistance in colorectal cancer

Mol Ther Nucleic Acids22100410152020

10.1016/j.omtn.2020.10.018

33251049

Maqbool

Lone

Ul Hussain

Post-transcriptional regulation of the tumor suppressor p53 by a novel miR-27a, with implications during hypoxia and tumorigenesis

Biochem J473359736102016

10.1042/BCJ20160359

27531966

Rokavec

Jiang

Horst

Hermeking

Antagonistic effects of p53 and HIF1A on microRNA-34a regulation of PPP1R11 and STAT3 and hypoxia-induced epithelial to mesenchymal transition in colorectal cancer cells

Gastroenterology1535055202017

10.1053/j.gastro.2017.04.017

28435028

Kiyonari

Iimori

Matsuoka

Watanabe

Morikawa-Ichinose

Miura

Niimi

Saeki

Tokunaga

Oki

The 1,2-diaminocyclohexane carrier ligand in oxaliplatin induces p53-dependent transcriptional repression of factors involved in thymidylate biosynthesis

Mol Cancer Ther14233223422015

10.1158/1535-7163.MCT-14-0748

26208523

Moradi Marjaneh

Khazaei

Ferns

Avan

Aghaee-Bakhtiari

MicroRNAs as potential therapeutic targets to predict responses to oxaliplatin in colorectal cancer: From basic evidence to therapeutic implication

IUBMB Life71142814412019

10.1002/iub.2108

31322820

Islam

Ahmed

Sonn

Jin

Lee

PRP4 induces epithelial-mesenchymal transition and drug resistance in colon cancer cells via activation of p53

Int J Mol Sci2330922022

10.3390/ijms23063092

35328513

Wei

Jiang

Song

A miR-210-3p regulon that controls the Warburg effect by modulating HIF-1α and p53 activity in triple-negative breast cancer

Cell Death Dis117312020

10.1038/s41419-020-02952-6

32908121

Nersisyan

Galatenko

Chekova

Tonevitsky

Hypoxia-induced miR-148a downregulation contributes to poor survival in colorectal cancer

Front Genet126624682021

10.3389/fgene.2021.662468

34135940

Ullmann

Qureshi-Baig

Rodriguez

Ginolhac

Nonnenmacher

Ternes

Weiler

Gäbler

Bahlawane

Hiller

Hypoxia-responsive miR-210 promotes self-renewal capacity of colon tumor-initiating cells by repressing ISCU and by inducing lactate production

Oncotarget765454654702016

10.18632/oncotarget.11772

27589845

Evert

Pathak

Sun

Zhang

A study on effect of oxaliplatin in MicroRNA expression in human colon cancer

J Cancer9204620532018

10.7150/jca.24474

29896290

Yamakuchi

Lotterman

Bao

Hruban

Karim

Mendell

Huso

Lowenstein

P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis

Proc Natl Acad Sci USA107633463392010

10.1073/pnas.0911082107

20308559

Wang

Zhao

Sun

Wang

Sun

Upregulation of MiR-205 under hypoxia promotes epithelial-mesenchymal transition by targeting ASPP2

Cell Death Dis7e25172016

10.1038/cddis.2016.412

27929537

Jin

Yang

Wei

Wang

Zhu

Wang

Zen

HIF-1α-induced miR-23a~27a~24 cluster promotes colorectal cancer progression via reprogramming metabolism

Cancer Lett4404412112222019

Qian

Yin

Wang

Zhang

Shi

MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers

Cell Cycle12138513942013

10.4161/cc.24477

23574723

Wang

Zhang

Hypoxia-inducible microRNA-224 promotes the cell growth, migration and invasion by directly targeting RASSF8 in gastric cancer

Mol Cancer16352017

10.1186/s12943-017-0603-1

28173803

Chen

Lin

Chung

Lang

Lin

Huang

Wang

Lin

Chen

Huang

miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4

Cancer Res72363136412012

10.1158/0008-5472.CAN-12-0667

22593189

Sun

Zhang

Yuan

Chen

Guo

Shao

Dang

Zhou

Wang

MiR-103a-3p promotes tumour glycolysis in colorectal cancer via hippo/YAP1/HIF1A axis

J Exp Clin Cancer Res392502020

10.1186/s13046-020-01705-9

33218358

Tang

Weng

Liu

Chen

Hypoxia enhances activity and malignant behaviors of colorectal cancer cells through the STAT3/MicroRNA-19a/PTEN/PI3K/AKT axis

Anal Cell Pathol (Amst)202141324882021

34796092

Kim

Park

Lee

Kim

Park

Hypoxia-induced microRNA-590-5p promotes colorectal cancer progression by modulating matrix metalloproteinase activity

Cancer Lett41631412018

10.1016/j.canlet.2017.12.018

29247825

Chen

Qiu

Yuan

Sun

Liang

Yin

miR-503-5p confers drug resistance by targeting PUMA in colorectal carcinoma

Oncotarget821719217322017

10.18632/oncotarget.15559

28423513

Saieva

Barreca

Zichittella

Prado

Tripodi

Alessandro

Conigliaro

Hypoxia-induced miR-675-5p supports β-catenin nuclear localization by regulating GSK3-β activity in colorectal cancer cell lines

Int J Mol Sci2138322020

10.3390/ijms21113832

32481626

Costa

Lo Dico

Rizzo

Rajata

Tripodi

Alessandro

Conigliaro

MiR-675-5p supports hypoxia induced epithelial to mesenchymal transition in colon cancer cells

Oncotarget824292243022017

10.18632/oncotarget.14464

28061476

Poel

Boyd

LNC

Beekhof

Schelfhorst

Pham

Piersma

Knol

Jimenez

Verheul

HMW

Buffart

Proteomic analysis of miR-195 and miR-497 replacement reveals potential candidates that increase sensitivity to oxaliplatin in MSI/P53wt colorectal cancer cells

Cells811112019

10.3390/cells8091111

31546954

Dong

Zhao

Zhang

Liu

Kang

Leung

Zhang

Chan

Sung

Tumor suppressor functions of miR-133a in colorectal cancer

Mol Cancer Res11105110602013

10.1158/1541-7786.MCR-13-0061

23723074

Moriondo

Scioscia

Soccio

Tondo

De Pace

Sabato

Foschino Barbaro

Lacedonia

Effect of hypoxia-induced micro-RNAs expression on oncogenesis

Int J Mol Sci2362942022

10.3390/ijms23116294

35682972

Wang

Lan

Lai

Yao

Liu

Lai

Yan

LncRNA SNHG6 promotes chemoresistance through ULK1-induced autophagy by sponging miR-26a-5p in colorectal cancer cells

Cancer Cell Int192342019

10.1186/s12935-019-0951-6

31516391

Liu

Chen

Zhou

Weng

Tan

Shen

Zhou

MicroRNAs that regulate PTEN as potential biomarkers in colorectal cancer: A systematic review

J Cancer Res Clin Oncol1468098202020

10.1007/s00432-020-03172-3

32146564

Chen

Lin

Zeng

Liu

Pan

Sun

lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer

J Hematol Oncol1232019

10.1186/s13045-018-0690-5

30626446

Gao

Liu

Xie

Guo

Tang

Xie

MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1

PLoS One8e651382013

10.1371/annotation/4c8d2e73-67b1-473d-ae8e-4f847a5f7ef8

23750239

Yang

Zhang

Zhao

Yang

Jiang

Fan

Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer

Cancer Biol Ther175155252016

10.1080/15384047.2015.1095405

26492332

Rokavec

Öner

Jackstadt

Jiang

Lodygin

Kaller

Horst

Ziegler

Schwitalla

IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis

J Clin Invest124185318672014

10.1172/JCI73531

24642471

Werner

Hart

Nickels

Kim

Menger

Bohle

Keller

Ludwig

Meese

MiR-34a-3p alters proliferation and apoptosis of meningioma cells in vitro and is directly targeting SMAD4, FRAT1 and BCL2

Aging (Albany NY)99329542017

10.18632/aging.101201

28340489

Velaei

Samadi

Barazvan

Soleimani Rad

Tumor microenvironment-mediated chemoresistance in breast cancer

Breast30921002016

10.1016/j.breast.2016.09.002

27668856

Scholten

IITimmer

Peacock

Pelle

Williams

Steensma

Down regulation of Wnt signaling mitigates hypoxia-induced chemoresistance in human osteosarcoma cells

PLoS One9e1114312014

10.1371/journal.pone.0111431

25347326

Muz

Kusdono

Azab

de la Puente

Federico

Fiala

Vij

Salama

Azab

Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance

Leuk Lymphoma58291629252017

10.1080/10428194.2017.1319052

28509582

Mirnezami

Pickard

Zhang

Primrose

Packham

MicroRNAs: Key players in carcinogenesis and novel therapeutic targets

Eur J Surg Oncol353393472009

10.1016/j.ejso.2008.06.006

18644693

Munk

Panda

Grammatikakis

Gorospe

Abdelmohsen

Senescence-associated MicroRNAs

Int Rev Cell Mol Biol3341772052017

10.1016/bs.ircmb.2017.03.008

28838538

Vienberg

Geiger

Madsen

Dalgaard

MicroRNAs in metabolism

Acta Physiol (Oxf)2193463612017

10.1111/apha.12681

27009502

Shen

Zheng

Fan

The role and mechanisms of action of microRNAs in cancer drug resistance

Clin Epigenetics11252019

10.1186/s13148-018-0587-8

30744689

Tiwari

Mukherjee

Dixit

MicroRNA key to angiogenesis regulation: MiRNA biology and therapy

Curr Cancer Drug Targets182662772018

10.2174/1568009617666170630142725

28669338

Oikawa

Otsuka

Sabe

p53-dependent and -independent epithelial integrity: beyond miRNAs and metabolic fluctuations

Cancers (Basel)101622018

10.3390/cancers10060162

29799511

Blume

Hotz-Wagenblatt

Hüllein

Sellner

Jethwa

Stolz

Slabicki

Lee

Sharathchandra

Benner

p53-dependent non-coding RNA networks in chronic lymphocytic leukemia

Leukemia29201520232015

10.1038/leu.2015.119

25971364

Ueno

Toyooka

Fukazawa

Kubo

Soh

Asano

Muraoka

Tanaka

Maki

Shien

Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma

Acta Med Okayama6823262014

24553485

Suh

Chen

Zaman

Hirata

Yamamura

Shahryari

Liu

Tabatabai

Kakar

Deng

MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer

Carcinogenesis327727782011

10.1093/carcin/bgr036

21349819

Huang

Kesselman

Kizub

Guerrero-Preston

Ratovitski

Phospho-ΔNp63α/microRNA feedback regulation in squamous carcinoma cells upon cisplatin exposure

Cell Cycle126846972013

10.4161/cc.23598

23343772

Bisio

De Sanctis

Del Vescovo

Denti

Jegga

Inga

Ciribilli

Identification of new p53 target microRNAs by bioinformatics and functional analysis

BMC Cancer135522013

10.1186/1471-2407-13-552

24256616

Suzuki

Yamagata

Sugimoto

Iwamoto

Kato

Miyazono

Modulation of microRNA processing by p53

Nature4605295332009

10.1038/nature08199

19626115

Kulshreshtha

Ferracin

Wojcik

Garzon

Alder

Agosto-Perez

Davuluri

Liu

Croce

Negrini

A microRNA signature of hypoxia

Mol Cell Biol27185918672007

10.1128/MCB.01395-06

17194750

Liao

Cao

Zhou

New insights into p53 functions through its target microRNAs

J Mol Cell Biol62062132014

10.1093/jmcb/mju018

24740682

Rokavec

Jiang

Hermeking

The p53/microRNA connection in gastrointestinal cancer

Clin Exp Gastroenterol73954132014

25328413

Sun

Xia

Zhao

Wang

Huang

Sun

Hypoxia-induced down-regulation of microRNA-34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells

PLoS One7e307712012

10.1371/journal.pone.0030771

22363487

Zhou

Wei

Shi

Huang

Gao

Zhang

Wei

MiR-26a inhibits cell proliferation and induces apoptosis in human bladder cancer through regulating EZH2 bioactivity

Int J Clin Exp Pathol1011234112412017

31966476

Zhang

Wang

Liu

Yang

Wang

MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2

Mol Cancer Ther167397512017

10.1158/1535-7163.MCT-16-0591

28069878

Sun

Wang

Zhang

Jia

Yao

Qiao

miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy via transforming growth factor-β/Smad4 pathway

World J Gastroenterol23181618272017

10.3748/wjg.v23.i10.1816

28348487

Shi

Kaller

Rokavec

Kirchner

Horst

Hermeking

Characterization of a p53/miR-34a/CSF1R/STAT3 feedback loop in colorectal cancer

Cell Mol Gastroenterol Hepatol103914182020

10.1016/j.jcmgh.2020.04.002

32304779

Wang

Liu

Mei

Wang

Liang

Cui

Yang

Liu

Interleukin 22 protects colorectal cancer cells from chemotherapy by activating the STAT3 pathway and inducing autocrine expression of interleukin 8

Clin Immunol1541161262014

10.1016/j.clim.2014.07.005

25063444

Jahid

Sun

Edwards

Dizon

Panarelli

Milsom

Sikandar

Gümüs

Lipkin

miR-23a promotes the transition from indolent to invasive colorectal cancer

Cancer Discov25405532012

10.1158/2159-8290.CD-11-0267

22628407

Huang

Ding

Liang

Zhao

Zhang

Yao

Pan

Zhang

Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells

Int J Cancer1239729782008

10.1002/ijc.23580

18508316

Liao

Wang

Nie

Bai

Mei

Han

Elevated microRNA-23a expression enhances the chemoresistance of colorectal cancer cells with microsatellite instability to 5-fluorouracil by directly targeting ABCF1

Curr Protein Pept Sci163013092015

10.2174/138920371604150429153309

25929864

Peng

Zhang

Tan

miR-23a promotes cisplatin chemoresistance and protects against cisplatin-induced apoptosis in tongue squamous cell carcinoma cells through twist

Oncol Rep339429502015

10.3892/or.2014.3664

25501015

Wang

Cao

Sinomenine inhibits proliferation, migration, invasion and promotes apoptosis of prostate cancer cells by regulation of miR-23a

Biomed Pharmacother1121085922019

10.1016/j.biopha.2019.01.053

30784907

Zhang

Wang

Zhang

Tang

Proliferation, migration and apoptosis of acute myeloid leukemia cells regulated by mir-23a-3p targeting SMC1A and the mechanism

Zhonghua Zhong Liu Za Zhi417537592019(In Chinese)

31648497

Figure 1.

Hypoxia reduces OXA sensitivity in CRC cells. HCT116 and HT29 cells were treated with 5, 10, 20, 40 and 60 µM OXA for 24 h and the cell proliferation under normoxia and hypoxia was measured. (A) Cellular growth inhibition rates. Black dotted box: 20 µM OXA treatment group. (B) The cellular growth inhibition rates of HCT116 and HT29 cells in the 20 µM OXA treatment group were shown separately. It was clear that HCT116 cells were more sensitive to OXA than HT29 cells under normoxic condition. (C) Growth inhibition change rate indicated that hypoxia generated a greater impact on the OXA sensitivity of HCT116 cells than HT29 cells. *P<0.05 and **P<0.01. Dotted boxes, a moderate dose of 20 µM OXA was selected as a standard dose and used in the following experiments. OXA, oxaliplatin; CRC, colorectal cancer; Nor, normoxia; Hyp, hypoxia.

Figure 2.

Western blot analysis of P53 protein expression levels in HCT116 and HT29 cells treated with OXA or hypoxia. (A) After treated with 20 µM OXA, the P53 level of HCT116 cells increased significantly and of HT29 cells did not change considerably. Upper panel, western blot band; histograms, the relative band density. (B) After treated with hypoxia, the P53 level of HCT116 cells increased significantly and of HT29 cells did not change considerably. Upper panel, western blot band; histograms, the relative band density. **P<0.01. Nor, normoxia; Hyp, hypoxia. OXA, oxaliplatin; Nor, normoxia; Hyp, hypoxia; NS, not significant.

Figure 3.

P53^WT affects HCT116 cell drug sensitivity. (A) Western blotting results showed the knocking down efficacy of P53. (B) Knocking down P53 enhanced HCT116 cell drug sensitivity under normoxic condition but reduced cell drug sensitivity under hypoxic condition. However, knocking down P53 did not change HT29 cell response to OXA under either normoxia or hypoxia. (C) Cellular growth inhibition rate also reflected that knocking down P53 affects the response of HCT116 cells to OXA under hypoxia. *P<0.05 and **P<0.01. OXA, oxaliplatin; NS, not significant; Nor, normoxia; Hyp, hypoxia.

Figure 4.

Reverse transcription-quantitative PCR is applied to detect miR expression level changes in HCT116 cells treated with OXA or hypoxia and to find the P53-related miRs in P53-knocked down HCT116 cells. (A) The expression level of miR-143, 26a, 34a, 133a, 149 and 195 increased significantly after HCT116 cells were treated with 20 µM OXA for 24 h. (B) The expression level of miR-23a, 27a, 107, 19a, 145, 205, 210 and 590 increased significantly after HCT116 cells were treated with hypoxia for 24 h. (C) With P53_WT knocked down, the expression levels of miR-26a, 34a and 133a (in bold type) were decreased in the OXA treatment group. (D) With P53_WT knocked down, the expression levels of miR-23a, 107 and 205 (in bold type) were decreased in the hypoxia treatment group. *P<0.05 and **P<0.01. OXA, oxaliplatin; miR, microRNA; NS, not significant; Nor, normoxia; Hyp, hypoxia.

Figure 5.

miR23a, 26a, 34a, 133a, 107 and 205 are overexpressed in HCT116 cells. miR-23a decreased cell growth inhibition, whereas miR-26a and miR-34a increased cell growth inhibition. However, miR-133a, 107 and 205 did not affect cell growth inhibition. **P<0.01. miR, microRNA; OXA, oxaliplatin; NS, not significant; NC, negative control.

Figure 6.

miRs affect colorectal cancer cell drug sensitivity depending on P53_WT. (A) Reverse transcription-quantitative PCR results indicated that OXA or hypoxia did not promote the expression level of miR-26a, 34a and 23a in HT29 cells. (B) The effect of miRs on HT29 cell drug sensitivity was measured by cell growth inhibition assay. The results indicated that miR-23a decreased cell growth inhibition, whereas miR-26a and 34a increased cell growth inhibition. (C) P53_WT was introduced in to HT29 cell and confirmed by western blotting. (D) After introducing exogenous P53_WT to HT29 cells, miR-26a, 34a and 23a could be induced by OXA or hypoxia treatment. *P<0.05 and **P<0.01. miR, microRNA; NS, not significant; Nor, normoxia; Hyp, hypoxia; EV, empty vector.

Figure 7.

Hypoxia suppresses expression of miR-26a and miR-34a. Expression levels of miR-26a and miR-34a in hypoxia-treated HCT116 and HT29 cells were analyzed by reverse transcription-quantitative PCR. (A and B) The results indicated that hypoxia significantly suppressed the expression of miR-26a and miR-34a in both (A) HCT116 and (B) HT29 cells. However, administration of echinomycin reversed the hypoxic inhibition effect in (A) HCT116 but not in (B) HT29 cells. miR, microRNA; Nor, normoxia; Hyp, hypoxia.

Figure 8.

miRs regulate cell apoptotic factors and modulate drug sensitivity. (A) miR-26a decreased the expression levels of MCL-1, EZH2 and BCL-2 and (B) miR-34a decreased the expression levels of SMAD4, STAT3 and BCL-2. (C) However, overexpressing miR-23a may reverse the inhibition of MCL-1 and BCL-2 that were induced by miR-23a/34a. These data possibly explain how P53_WT-induced miRs promote drug sensitivity and why hypoxia enhances drug resistance in CRC cells. miR, microRNA; OXA, oxaliplatin; NC, negative control.

Figure 9.

Schematic of the molecular mechanisms of p53-miRs cross-talking regulating OXA chemosensitivity in hypoxia: OXA and low O₂ as two stress conditions drive P53 to modulate different miR groups and thus activate distinct cellular signaling pathways. miR, microRNA; OXA, oxaliplatin.

Table I.

miRs and primer sequences.

Chemoresistance-related miRs	Primer sequence (5′→3′)	(Refs.)
hsa-miR-149-5p	TCTGGCTCCGTGTCTTCACTCC	(27)
hsa-miR-150-5p	TCTCCCAACCCTTGTACCAGTG	(27)
hsa-miR-34a-5p	TGGCAGTGTCTTAGCTGGTTGTT	(30,31)
hsa-miR-34c-5p	AGGCAGTGTAGTTAGCTGATT	(36)
hsa-miR-519d-3p	CAAAGTGCCTCCCTTTAGAGT	(36)
hsa-miR-204-5p	ACTCGTGGACTTCCCTTTGT	(36)
hsa-miR-143-3p	TGAGATGAAGCACTGTAGCT	(31,40)
hsa-miR-153-3p	TTGCATAGTCACAAAAGTGAT	(31)
hsa-miR-27a-3p	TCACAGTGGCTAAGTTCCG	(31)
hsa-miR-218-5p	TTGTGCTTGATCTAACCATGT	(31)
hsa-miR-520a-5p	CTCCAGAGGGAAGTACTTTCT	(31)
hsa-miR-503-5p	TAGCAGCGGGAACAGTTCTGCAG	(46)
hsa-miR-195-5p	CTGACCTATGAATTGACAGCC	(49)
hsa-miR-133a-3p	TTTGGTCCCCTTCAACCAGCT	(50)
hsa-miR-26a-5p	TTCAAGTAATCCAGGATAGGCT	(52,53)

Chemoresistance-related miRs	Primer sequence (5′→3′)	(Refs.)

hsa-miR-27a-3p	TCACAGTGGCTAAGTTCCG	(28)
hsa-miR-34a-5p	TGGCAGTGTCTTAGCTGGTTGTT	(29)
hsa-miR-210-3p	CTGTGCGTGTGACAGCGGCTGA	(32–35)
hsa-miR-107	AGCAGCATTGTACAGGGCTATCA	(37)
hsa-miR-205-5p	TCCTTCATTCCACCGGAGTCTG	(38)
hsa-miR-338-5p	AACAATATCCTGGTGCTGAGTG	(17)
hsa-miR-23a-3p	ATCACATTGCCAGGGATTTCC	(39)
hsa-miR-224-5p	TCAAGTCACTAGTGGTTCCGTT	(41)
hsa-miR-107	AGCAGCATTGTACAGGGCTATCA	(42)
hsa-miR-103a-3p	AGCAGCATTGTACAGGGCTATGA	(42,43)
hsa-miR-19a-3p	TGTGCAAATCTATGCAAAAC	(44)
hsa-miR-590-5p	GAGCTTATTCATAAAAGTGCA	(45)
hsa-miR-675-5p	TGGTGCGGAGAGGGCCCACA	(47,48)
hsa-miR-145-5p	GTCCAGTTTTCCCAGGAATC	(51)
hsa-miR-27b-3p	TTCACAGTGGCTAAGTTCTG	(51)
hsa-miR-26a-5p	TTCAAGTAATCCAGGATAGGCT	(51)

miR, microRNA; hsa, Homo sapiens.